Post by
Slinger14 on Nov 12, 2015 9:46am
CXR diamond in the rough
CXR has definitely been the gem of the Canadian health sector as of late. VRX and NHC are continuing to get beaten up. VRX is back under $100 right now and NHC is being obliterated and is now sub $4.00 again. CXR has not seen this volatility in over a week and new BUY ratings come out every day. I think investors' fear is starting to dissipate on CXR. Hopefully we get a boost because of earnings release today. It may increase the trading range a bit until next earnings release, when, in my opinion, we still see the stock start to take off. Hopefully it happens even sooner! Good luck!
Comment by
argentia77 on Nov 12, 2015 12:35pm
Slinger7 said: CXR has definitely been the gem of the Canadian health sector as of late. I disagree. Prometric Life Sciences (PLI) another Canadian bio-pharm (Cap 1.5B) has seen its sp rise 75% since Oct 15.
Comment by
Slinger14 on Nov 12, 2015 12:43pm
I should've been more specific and said very recently and performed better than the more notable companies such as VRX, NHC, PHM, etc who have suffered from short attacks as well. Sometimes I forget that others aren't thinking the exact same thing as me and when I write it, it comes out way too vague!
Comment by
sunshine7 on Nov 12, 2015 1:07pm
sold my PLI stake at $2.65 when it was technically over bought and bumped up on antidotal news of a child that survived treatment. Expanded applications help maintain the increase. Rolled my proceeds into CXR who I think have a more established business that is over sold for non-material reasons. Both I think have long term potential... for different reasons. Both good investments IMO.